Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Pharma
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
Amgen returned Kyowa's OX40 drug. Roche inked an RNAi deal with Sanegene. Daiichi discontinued its first non-DXd candidate. And more.
Angus Liu
Feb 6, 2026 9:48am
Alnylam drafts $250M upgrade to its Mass. drug factory
Dec 17, 2025 10:12am
Alnylam's ATTR-CM launch blows past estimates again
Oct 30, 2025 8:00am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
Novartis, Sarepta tipped to drive genomic therapy sales boom
May 15, 2025 12:18pm
Sanofi scores FDA nod for Qfitlia for all types of hemophilia
Mar 28, 2025 3:21pm
